49
Articles Count
4747
Viewing Count
Elise Mak

A China observer

SciClone licenses Tarveda's preclinical HSP90-PI3K...
Elise Mak · 4 days ago
SciClone has licensed in the Greater China rights to a preclinical-stage product portfolio of miniature drug conjugates that consist of a PI3K inhibitor payload moiety, a linker, and an HSP90 binding moiety.
Further information
News
IASO bags $108M Series C to advance cell therapy
Elise Mak · 4 days ago
The CAR-T therapy developer has raised more than $178 million since its establishment in 2017.
Further information
News
After mRNA, Everest gains BTK inhibitor in $561M d...
Elise Mak · 4 days ago
Everest will pay Suzhou Sinovent and SinoMab BioScience up to $561 million to license the global rights to BTK inhibitor XNW1011, four days after the mRNA transaction with Providence that is worth over $500 million.
Further information
News
Partnership with Providence “immediately establis...
Elise Mak · 5 days ago
Everest Medicines is the latest to join the course by tapping the mRNA technology, an area that Chinese players are flocking to.
Further information
Feature
BeiGene's Brukinsa wins FDA approval in marginal z...
Elise Mak · 5 days ago
BeiGene's BTK inhibitor Brukinsa received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (r/r) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
Further information
News
InnoCare seeks $621M STAR listing
Elise Mak · 5 days ago
Cancer drug developer InnoCare, known for its BTK inhibitor Yinuokai (orelabrutinib), is now seeking to raise RMB4 billion ($621 million) on Shanghai's STAR market.
Further information
News
South Australia an ideal start for biotech R&D
Elise Mak · 6 days ago
Representatives of these players offered their insights to Chinese biotech companies at the South Australia ∙ Clinical Trials Ecosystem – China Event Series zoom webinar on Sep. 13.
Further information
Feature
Alebund bags $54.5M Series B+ to target renal dise...
Elise Mak · 6 days ago
Alebund Pharmaceuticals, a renal disease specialist based in Shanghai, has secured $54.5 million in a Series B+ round to support its clinical programs and construction of a manufacturing site. The pro
Further information
News
MingMed raises $50M Series A+ to support U.S. eye ...
Elise Mak · 6 days ago
MingMed, which was founded in October 2019, boasts a pipeline that covers ophthalmology, small molecule immuno-oncology, gene editing-based immunotherapy, medical aesthetics, and pet medicine.
Further information
News
Cytovia and its China JV secures $45M to develop N...
Elise Mak · 6 days ago
Cytovia Therapeutics and its Chinese joint venture CytoLynx Therapeutics have raised $45 million to move their cell therapy candidates to IND stage and support the trials.
Further information
News
READ MORE

Personal Information

Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement